Journal article
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement
Abstract
AIMS: Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD).
METHODS: This study included Part A: 10 healthy volunteers randomized to single oral doses of losmapimod (7.5 mg then 15 mg; n = 8) or placebo (both periods; n = 2); Part B: 15 FSHD subjects randomized to placebo (n = 3), or losmapimod 7.5 mg (n = 6) or 15 mg (n = 6); and Part C: FSHD …
Authors
Mellion ML; Ronco L; Berends CL; Pagan L; Brooks S; van Esdonk MJ; van Brummelen EMJ; Odueyungbo A; Thompson LA; Hage M
Journal
British Journal of Clinical Pharmacology, Vol. 87, No. 12, pp. 4658–4669
Publisher
Wiley
Publication Date
December 2021
DOI
10.1111/bcp.14884
ISSN
0306-5251